​

10x Genomics (TXG) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

TXG Stock Forecast

10x Genomics (TXG) stock forecast, based on 22 Wall Street analysts, predicts a 12-month average price target of $83.30, with a high of $110.00 and a low of $65.00. This represents a 14.17% increase from the last price of $72.96.

$10 $30 $50 $70 $90 $110 High: $110 Avg: $83.3 Low: $65 Last Closed Price: $72.96

TXG Stock Rating

10x Genomics stock's rating consensus is Hold, based on 22 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 10 Buy (45.45%), 11 Hold (50.00%), 1 Sell (4.55%), and 0 Strong Sell (0.00%).

Hold
Total 22 0 1 11 10 Strong Sell Sell Hold Buy Strong Buy

TXG Price Target Upside V Benchmarks

TypeNameUpside
Stock10x Genomics14.17%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts71429
Avg Price Target$90.00$73.57$49.52
Last Closing Price$72.96$72.96$72.96
Upside/Downside23.36%0.84%-32.13%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 261612--19
Sep, 261510--16
Aug, 261510--16
Jul, 261510--16
Jun, 261510--16
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 13, 2026Stifel Nicolaus$70.00$72.68-3.69%-4.06%
Oct 12, 2026Morgan Stanley$70.00$78.95-11.34%-4.06%
Oct 12, 2026Kyle MiksonCanaccord Genuity$100.00$80.6523.99%37.06%
Oct 07, 2026Barclays$110.00$80.6636.37%50.77%
Sep 29, 2026Leerink Partners$90.00$88.431.78%23.36%
Sep 28, 2026Argus Research$110.00$85.7128.34%50.77%
Sep 28, 2026Piper Sandler$80.00$85.71-6.66%9.65%
Sep 09, 2026Doug SchenkelUBS$68.00$65.603.66%-6.80%
Sep 01, 2026Dan LeonardRBC Capital$70.00$62.4512.09%-4.06%
Aug 12, 2026Mason CarricoStephens$65.00$58.3411.42%-10.91%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 13, 2026Cowen & Co.HoldHoldhold
Oct 07, 2026BarclaysOverweightOverweighthold
Sep 28, 2026Piper SandlerNeutralNeutralhold
Sep 01, 2026RBC CapitalSector Performinitialise
Aug 12, 2026StephensOverweightOverweighthold
Aug 10, 2026Piper SandlerNeutralNeutralhold
Aug 07, 2026CitigroupNeutralNeutralhold
Jul 15, 2026Cowen & Co.HoldHoldhold
Jul 08, 2026CitigroupNeutralNeutralhold
Jun 24, 2026BarclaysOverweightOverweighthold

Financial Forecast

EPS Forecast

Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-0.53$-1.46$-2.18$-1.52$-0.35---
Avg Forecast$-0.46$-1.62$-2.14$-1.41$-1.27$-0.91$-0.86$-1.07
High Forecast$-0.43$-1.55$-1.73$-1.35$-1.12$-0.04$-0.71$-1.01
Low Forecast$-0.49$-1.68$-2.31$-1.47$-1.52$-1.41$-1.09$-1.13
Surprise %15.22%-9.88%1.87%7.80%-72.44%---

Revenue Forecast

$450M $530M $610M $690M $770M $850M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$490.49M$516.41M$618.73M$610.78M$642.82M---
Avg Forecast$493.74M$508.11M$616.72M$604.92M$630.74M$687.60M$739.28M$791.90M
High Forecast$519.37M$521.63M$617.30M$611.79M$659.73M$688.66M$746.52M$829.91M
Low Forecast$462.60M$491.46M$615.68M$598.81M$608.74M$686.53M$732.03M$761.89M
Surprise %-0.66%1.63%0.32%0.97%1.92%---

Net Income Forecast

$-350M $-280M $-210M $-140M $-70M $0 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-58.22M$-166.00M$-255.10M$-182.63M$-43.54M---
Avg Forecast$-64.96M$-86.08M$-255.10M$-165.42M$-158.30M$-119.69M$-105.37M$-124.98M
High Forecast$-51.97M$-68.86M$-204.08M$-158.48M$-131.42M$-4.13M$-83.35M$-118.82M
Low Forecast$-77.95M$-103.29M$-306.12M$-172.36M$-177.53M$-165.29M$-127.39M$-132.77M
Surprise %-10.37%92.85%-10.40%-72.49%---

TXG Forecast FAQ

Is 10x Genomics stock a buy?

10x Genomics stock has a consensus rating of Hold, based on 22 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 10 Buy, 11 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that 10x Genomics is a neutral investment for most analysts.

What is 10x Genomics's price target?

10x Genomics's price target, set by 22 Wall Street analysts, averages $83.3 over the next 12 months. The price target range spans from $65 at the low end to $110 at the high end, suggesting a potential 14.17% change from the previous closing price of $72.96.

How does 10x Genomics stock forecast compare to its benchmarks?

10x Genomics's stock forecast shows a 14.17% upside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for 10x Genomics over the past three months?

  • October 2026: 5.26% Strong Buy, 31.58% Buy, 63.16% Hold, 0% Sell, 0% Strong Sell.
  • September 2026: 6.25% Strong Buy, 31.25% Buy, 62.50% Hold, 0% Sell, 0% Strong Sell.
  • August 2026: 6.25% Strong Buy, 31.25% Buy, 62.50% Hold, 0% Sell, 0% Strong Sell.

What is 10x Genomics’s EPS forecast?

10x Genomics's average annual EPS forecast for its fiscal year ending in December 2026 is $-0.91, marking a 160.00% increase from the reported $-0.35 in 2025. Estimates for the following years are $-0.86 in 2027, and $-1.07 in 2028.

What is 10x Genomics’s revenue forecast?

10x Genomics's average annual revenue forecast for its fiscal year ending in December 2026 is $687.6M, reflecting a 6.97% increase from the reported $642.82M in 2025. The forecast for 2027 is $739.28M, and $791.9M for 2028.

What is 10x Genomics’s net income forecast?

10x Genomics's net income forecast for the fiscal year ending in December 2026 stands at $-120M, representing an 174.88% increase from the reported $-43.544M in 2025. Projections indicate $-105M in 2027, and $-125M in 2028.